ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer—Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study

Sherko Kuemmel, Peter A. Fasching, Peter Schmid, Nadia Harbeck, Masato Takahashi, Michael Untch, Jean-Francois Boileau, Javier Cortes, Rebecca Dent, Joyce O’Shaughnessy, Lajos Pusztai, Theodoros Foukakis, Yeon Hee Park, Rina Hui, Fatima Cardoso, Carsten Denkert, Liyi Jia, Wilbur Pan, Vassiliki Karantza, Heather McArthur

Open source

DOI: 10.1245/s10434-026-19310-z
Published: 2026-03-12
Container: Annals of Surgical Oncology
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1245/s10434-026-19310-z,
  title = {ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer—Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study},
  author = {Sherko Kuemmel and Peter A. Fasching and Peter Schmid and Nadia Harbeck and Masato Takahashi and Michael Untch and Jean-Francois Boileau and Javier Cortes and Rebecca Dent and Joyce O’Shaughnessy and Lajos Pusztai and Theodoros Foukakis and Yeon Hee Park and Rina Hui and Fatima Cardoso and Carsten Denkert and Liyi Jia and Wilbur Pan and Vassiliki Karantza and Heather McArthur},
  year = {2026},
  journal = {Annals of Surgical Oncology},
  doi = {10.1245/s10434-026-19310-z},
  url = {https://doi.org/10.1245/s10434-026-19310-z}
}

RIS

TY  - JOUR
TI  - ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer—Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study
AU  - Sherko Kuemmel
AU  - Peter A. Fasching
AU  - Peter Schmid
AU  - Nadia Harbeck
AU  - Masato Takahashi
AU  - Michael Untch
AU  - Jean-Francois Boileau
AU  - Javier Cortes
AU  - Rebecca Dent
AU  - Joyce O’Shaughnessy
AU  - Lajos Pusztai
AU  - Theodoros Foukakis
AU  - Yeon Hee Park
AU  - Rina Hui
AU  - Fatima Cardoso
AU  - Carsten Denkert
AU  - Liyi Jia
AU  - Wilbur Pan
AU  - Vassiliki Karantza
AU  - Heather McArthur
PY  - 2026
JO  - Annals of Surgical Oncology
DO  - 10.1245/s10434-026-19310-z
UR  - https://doi.org/10.1245/s10434-026-19310-z
ER  -

APA

Kuemmel, S., Fasching, P. A., Schmid, P., Harbeck, N., Takahashi, M., Untch, M., Boileau, J., Cortes, J., Dent, R., O’Shaughnessy, J., Pusztai, L., Foukakis, T., Park, Y. H., Hui, R., Cardoso, F., Denkert, C., Jia, L., Pan, W., Karantza, V., & McArthur, H. (2026). ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer—Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study. Annals of Surgical Oncology. https://doi.org/10.1245/s10434-026-19310-z

Source records

crossref · retrieved 2026-09-26T07:24:37.410Z